This event will offer a week of biotech, pharma and finance, including several very interesting on demand sessions.
The digital event, October 25-28, will include one-to-one meetings, company presentations, company showcases and interesting keynotes and panels. Global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy that enables them to meet and present to numerous potential partners.
BIO-Europe’s workshops, panels and exhibition, along with digital one-to-one meetings, make this an important event for the life science industry.
Global health: Partnering for a global win-win
The agenda includes several highly interesting on demand-session, for example Global Health: Partnering for a global win-win. The pandemic has made obvious like never before that healthcare at a global level affects the health of everyone at an individual level. This session will discuss how partnership across borders and sector divides can increase R&D to meet global unmet medical needs and increase access for underserved populations, even in disease areas and technologies that may not see huge commercial returns. Concentrating largely on vaccine provision and the increasing danger of AMR, how can industry, researchers, and public bodies combine efforts for effective interventions? Panelist include Amy Finan, CEO, Sabin Vaccine Institute, Penny Heaton, Head of Vaccines, Johnson & Johnson, and Fatema Rafiqi, AMR Benchmark Research Programme Manager, Access to Medicine Foundation.
Datasharing for collaboration
Another on demand session is Datasharing for collaboration. This session will examine at how data sharing between institutions, companies and across boarders impacts R&D, clinical trials and other elements of drug discovery and development. What infrastructure and harmonization of health research and systems can increase the efficiency and impact of life science knowledge building and collaboration? Panelist include Danny Bar-Zohar, Global Head of Development, Merck Healthcare KGaA, Peter Mesenbrink – Executive Director of Biostatistics, Novartis, Ray Pinto – Director for Digital Transformation, DIGITAL EUROPE and Manu Vohra – Managing Director, Box.
The future of gene therapies
Also part of the on demand sessions, there will be a roundtable discussion on the future of gene therapies. Gene therapies on a broad scale will be discussed and the panelist will dig deeper into issues around safety and how this key issue will affect the future development of gene therapies. Panelists include Regina Hodits – Managing Partner, Wellington Partners, Tomas Landh – Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation, Novo Nordisk and Samir Ounzain – CEO & Scientific Co-founder, HAYA Therapeutics SA.
Therapeutic areas in focus
The event will also focus on therapeutic areas. For example, the emergence of Long COVID has raised the profile of autoimmune diseases and has spurred research into the area in general. There is continued uncertainty about the causes of many of these diseases and their often chronic nature makes even diagnosis difficult. In the session A new light on autoimmune diseases it will be discussed what are currently the most promising areas of research? What insights has COVID research suggested for other conditions? How has increased awareness around these conditions impacted research and clinical development?
There will also be sessions about neurodegenerative diseases, the hot spot: advancements in neurodegenerative disease therapeutics, and oncology, Compelling deal making in a competitive oncology market.
Read more about BIO-Europe Digital 2021 here!